MRTX1133 was also evaluated in immunocompromised mice bearing tumor xenografts with the KRASG12D mutation to determine its effect on KRAS-mediated signaling and characterize its in vivo antitumor activity. The gene discussed is KRAS; the disease is neoplasm.